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S U M M A R Y
Objectives: Diabetes mellitus (DM) triples the risk of tuberculosis (TB) disease, complicates TB treatment,
and increases the risk of a poor TB outcome. As DM prevalence is increasing across the Middle East, this
review was performed to identify regional gaps in knowledge and research priorities for DM/TB.
Methods: Online databases were searched for studies published from Middle East countries on DM and
TB and the studies summarized based on topic and major ﬁndings. Studies included had a principle
hypothesis related to both diseases, or described TB patients with individual data on DM.
Results: Fifty-nine studies from 10 countries met search criteria. No published studies were found from
Lebanon, Bahrain, Syria, Jordan, Cyprus, or the United Arab Emirates. DM prevalence among TB patients
was high, but varied considerably across studies. The vast majority of studies were not speciﬁcally
designed to compare DM/TB and non-DM/TB patients, but many suggested worse treatment outcomes
for DM/TB, in accordance with reports from other regions.
Conclusions: Opportunity exists for the regional study of bidirectional screening, management strategies
for both DM and TB diseases, and whether such efforts could take place through the integration of
services.
 2015 The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-
nc-nd/4.0/).
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jou r nal h o mep ag e: w ww .e lsev ier . co m / loc ate / i j id1. Introduction
Diabetes mellitus (DM) is an increasingly recognized comor-
bidity that can both accelerate tuberculosis (TB) disease and
complicate TB treatment.1 DM triples the risk of developing active
TB following infection compared to patients without DM.2 Indeed,
in regions of the world with high DM prevalence, the risk of
developing TB disease attributable to DM exceeds even that of
HIV.3 Better understanding of the DM/TB dynamic led to the recent
World Health Organization (WHO) Collaborative Framework for
Care and Control of Tuberculosis and Diabetes,4 which emphasizes
bidirectional screening to identify latent TB infection in patients
with DM, or newly diagnose DM in patients with active TB.5 Such
interventions may ultimately lead to increased dual detection in
regions of high co-prevalence. Nevertheless, there are considerable* Corresponding author.
E-mail address: dr.yusra.alkabab@gmail.com (Y.M. Alkabab).
http://dx.doi.org/10.1016/j.ijid.2015.09.010
1201-9712/ 2015 The Authors. Published by Elsevier Ltd on behalf of International So
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).gaps in knowledge with regard to strategies for implementation of
bidirectional screening, as well as other more fundamental
questions related to pathophysiology and immunology, clinical
presentation, and treatment approach for both diseases in the DM/
TB host.
Importantly, these interventions must be regionally distinct
and will depend signiﬁcantly on the local epidemiology and
standards of care. The estimated number of prevalent TB cases in
the WHO Eastern Mediterranean Region (the region of most
overlap with the queried Middle East countries) has been reported
to be 1 000 000 (880 000–1 200 000). Comparatively, the
International Diabetes Foundation (IDF) has reported that in the
Middle East and North Africa alone, 35 million people are living
with DM. Figure 1 illustrates the top 10 countries for age-adjusted
prevalence of DM, three of which are in the Middle East (Saudi
Arabia, Kuwait, and Qatar).7 Yet despite this ecological association,
and relative to the potential magnitude of the public health
problem, DM/TB in the Middle East remains understudied.
Therefore, a literature review was conducted to summarize theciety for Infectious Diseases. This is an open access article under the CC BY-NC-ND
Figure 1. Of the top 10 countries with the highest age-adjusted prevalence of diabetes, three are in the Middle East. (Figure based on data from the International Diabetes
Federation.6)
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highlight region-speciﬁc gaps in knowledge, and to prioritize areas
for further investigation in the context of WHO recommendations.
2. Methods
While this study was not a meta-analysis, PRISMA guidelines
were adhered to whenever possible.8 The PubMed and Google
Scholar databases were searched using the following English-
language terms: ‘‘tuberculosis’’ AND ‘‘diabetes’’ AND/OR ‘‘middle
east’’ OR the following countries, ‘‘Iraq,’’ ‘‘Yemen,’’ ‘‘Kuwait,’’
‘‘Iran,’’ ‘‘Bahrain,’’ ‘‘Egypt,’’ ‘‘Syria,’’ ‘‘Turkey,’’ ‘‘Lebanon,’’ ‘‘Oman,’’
‘‘Qatar,’’ ‘‘Saudi Arabia,’’ ‘‘Israel,’’ ‘‘Jordan,’’ ‘‘UAE,’’ ‘‘Cyprus’’ OR
‘‘United Arabs Emirates.’’ As no consensus deﬁnition for ‘Middle
East’ countries exists, the United Nations deﬁnition for Western
Asia was employed, and Egypt and Turkey were also included.9
Reference sections of articles derived from the database search
were also checked for additional studies. The initial database
search was performed by one author (YMA), while two others
(HMA and SKH) agreed on the ﬁnal list for inclusion. All studies for
which there was access to full-text and that had a principle
hypothesis related to both diseases and/or any study of TB patients
that reported individual data on DM, were included. Articles
written in the English language were included and were grouped
by major topic and country of origin. A priori topics of interest
included regional DM/TB epidemiology, bidirectional screening,
clinical manifestations, immunology, pharmacokinetics, and man-
agement strategies.
3. Results
Fifty-nine studies were found that met the search criteria,
representing 10 separate countries.10–68 A total of 17 studies were
case–control studies comparing DM/TB to non-DM/TB
patients.16,19,25,28,30,36,37,42,44,47–51,54,55,65 Five studies were cross-
sectional,14,20,29,33,52 one was prospective,10 and the remainder
were retrospective studies evaluating the demographic and clinical
characteristics of TB-infected patients. Iran contributed the most
studies (16 studies) and the fewest were from Yemen and Oman
(one each). Importantly, no published studies were found from
Lebanon, Bahrain, Syria, Cyprus, Jordan, and the UAE. As only
English-language articles were included, abstracts were then
further searched in other regional languages (Arabic, Farsi, and
Turkish), which revealed one study in Farsi from Iran that was thenincluded.21 Table 1 summarizes the studies grouped by topic, the
important features of which are discussed in the following
sections.
3.1. Epidemiology
Analysis of the WHO and IDF country-level surveillance data
alongside that reported from the individual studies, demonstrated
a considerable co-prevalence of DM/TB (Table 2). Yemen leads the
region with regard to TB prevalence, and despite a comparatively
low DM prevalence, 21% of all TB patients in one study were
reported to have DM. The greatest numbers of studies of co-
prevalence were from Saudi Arabia, Iran, and Turkey, with
proportions varying from less than 10% to more than 30%.
3.2. Screening for TB in diabetic patients
Despite the apparent beneﬁt of bidirectional screening in other
settings,5 only one study from the Middle East was found that
speciﬁcally addressed this topic. The study had a cross-sectional
design and was conducted in a diabetes center in Iran; the principal
aim was to identify the number of smear-positive pulmonary TB
patients with DM.14 Four hundred patients with DM all received a
tuberculin skin test (TST). The test result was negative (induration
of 0–4 mm) in 257 patients (64.25%), intermediate (induration of
5–9 mm) in 118 patients (29.5%), and positive (induration of 10–
14 mm) in 25 patients (6.25%). Twenty-four of the 400 (6%) were
suspected to have TB by symptoms (cough >3 weeks, hemoptysis,
and fever) and underwent testing of sputum for acid-fast bacilli
(AFB) and a chest X-ray. Of the 24 suspected cases, four (one with
an intermediate TST and three with a positive TST) had a positive
sputum smear for AFB and the diagnosis of active TB was made. The
rate of detection of active TB was considered greater than the
expected community prevalence and the authors recommended
continued screening in all patients with DM. No other study was
found that addressed screening or treatment of latent TB infection
in DM patients, or active screening for the presence or severity of
DM in patients with known TB.
3.3. Immunology
Currently, it is understood that both the innate and adaptive
immune response are important in preventing progression from TB
infection to active disease, and DM may impair multiple aspects of
Table 1
Topic summaries of studies reviewed from the Middle East
Topic Studies and summary of ﬁndings
Epidemiology of DM/TB DM prevalence among TB patients ranged from 4% to 41%10–13,15,17,18,21,26–28,30,31,34,35,38,40,41,43,45,46,52–54,56–64,66–68
TB screening among patients with DM Only one study from Iran screened for active TB among patients with DM and found four cases in 400 patients, a rate
above the expected community prevalence14
Immunology Four studies, two from Kuwait36,37 and one each from Iraq28 and Iran,19 described cell-mediated immune dysregulation
in DM/TB patients
Clinical presentation The majority of studies found little difference in DM/TB patients and non-diabetic TB patients, although in some studies
patients with DM were older; studies conﬂicted with regard to sex differences or sputum smear status. In total,
10 studies addressed this topic: ﬁve from Turkey,42,48,49,51,52 two from Saudi Arabia,55,61 one from Egypt,30 one from
Iraq,28 and one from Iran16
Radiology Chest X-ray ﬁndings were highly variable and data were conﬂicting: studies reported more atypical presentation in DM/
TB compared to non-DMTB, others less, and still others reported no difference between the groups. In total, 10 studies
addressed this topic: three from Turkey,42,44,51 three from Saudi Arabia,53,54,65 two from Iran,6,26 one from Egypt,30 and
one from Iraq29
Association with Mycobacterium
tuberculosis drug resistance
Five studies commented on drug resistance, but none found DM to be an independent risk factor for MDR-TB: two from
Iran,16,27 and one each from Saudi Arabia,55 Turkey,42 and Israel67
Pharmacokinetics A single study from Turkey found signiﬁcantly reduced rifampicin and isoniazid exposure in DM/TB47
Sputum conversion Five studies assessed risk factors for sputum smear and/or culture conversion after starting TB treatment and favored
DM delaying a microbiological response to therapy: three studies from Turkey,42–44 and one each from Oman66 and
Saudi Arabia57
Treatment outcome While some studies showed no difference in TB treatment outcomes in patients with and without DM,29,39,55,61,67,68
others found that DM prolonged treatment duration42 and increased the risk of treatment failure,34 mortality,15,23 and
default.39 In total, 10 studies addressed this topic: two from Iran,15,23 two from Israel,67,68 two from Saudi Arabia,55,61
one from Turkey,42 one from Egypt,34 one from Kuwait,39 and one from Iraq29
DM, diabetes mellitus; TB, tuberculosis; MDR, multidrug-resistant.
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Middle East focused on the cell-mediated immune response in the
DM/TB disease state. A study from Iraq showed a signiﬁcant
decrease in the concentration of the cytokines interferon gamma
(IFN-g) and interleukin 2 (IL-2) in DM/TB patients compared to
non-diabetic TB patients.28 Additionally, a study from Iran
demonstrated a statistically signiﬁcant reduction in the total T-
lymphocyte population, particularly the T-helper sub-class, in DM/
TB patients compared with both non-diabetic TB patients and
healthy controls.19 Furthermore, a study from Kuwait found DM/
TB patients to have a lower Th1:Th2 cytokine ratio, leading to a
stronger Th2 bias, and this has been hypothesized elsewhere to
contribute to the faster clinical deterioration in DM/TB patients.36
Another study in Kuwait was conducted to evaluate cell-mediatedTable 2
Diabetes mellitus and tuberculosis epidemiology and country-speciﬁc citations
Country TB prevalence as the
rate per 100 000
population (range)6
DM prevalence as a
percentage of the
total population
aged 20–79 years7
Pe
DM
TB
inc
Yemen 60 (24–112) 8.45% 21
Qatar 37 (11–79) 22.87% 5–
Iran 32 (16–53) 9.9% 4.2
Iraq 29 (8.6–61) 9.5% 41
Egypt 27 (14–44) 16.8% 16
Kuwait 25 (7.3–52) 23.1% 29
Turkey 23 (11–39) 14.85% 7.9
Lebanon 16 (4.8–34) 15.0% No
Bahrain 15 (4.4–31) 21.8% No
Saudi Arabia 14 (4.3–30) 23.87% 14
Syria 14 (4.2–30) 8.91% No
Oman 13 (4.7–25) 14.24% 25
Israel 7.1 (2.9–13) 9.1% 5–
Cyprus 6.6 (2.2–13) 9.3% No
Jordan 5 (1.5–10) 11.4% No
UAE 1.3 (0.38–2.7) 18.98% No
TB, tuberculosis; DM, diabetes mellitus; SD, standard deviation; UAE, United Arab Emi
a Where there is only one study per country, the range (Iraq) or age category (Yemeresponses to complex, single secreted, and cytosolic antigens of
Mycobacterium tuberculosis and posited that only ESAT6 (6 kDa
early secretory antigenic target) could be useful in the diagnosis of
infection in both DM/TB and non-diabetic patients.37
3.4. Clinical presentation of DM/TB
The variation in DM/TB clinical presentation compared to TB
patients without DM has been commented on over many years,
with a focus on demographics, symptoms, anatomical distribution,
chest X-ray abnormalities, and the inﬂuence of DM severity and
glycemic control.70,72 Four studies (three case–control and one
cross-sectional) were found that reported that DM/TB patients
were older than non-diabetic TB patients, with the mean age ofrcentage range of
 prevalence among
 patients from studies
luded in this review
Range of study
time periods
Mean age  SD (years)
of the study populationa
% 10 2007–2010 <45 (89%)
45 (11%)
25.5% 11–13 1996–2009 34  4
–30% 15,17,18,21,26,27 1991–2008 44  5
.1% 28 2012–2013 52  10
.4–29.3% 30,31,34,35 2001–2011 47  6
.8–35% 38,40 1996–2005 37  6
–34% 41,43,45,46,52 1997–2010 41  4
 published studies
 published studies
–26% 53,54,56–64 1989–2009 47  13
 published studies
% 66 2001–2006 <20 (25%)
21–40 (37.5%)
41–60 (30.4%)
61 (7.1%)
12.9% 67,68 2000–2005 50  10
 published studies
 published studies
 published studies
rates.
n and Oman) is given, as reported in the published articles.
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reports outside the region, the majority of studies showed no
difference by sex,38,43,50,52 but two case–control studies, one from
Saudi Arabia54 and the other from Egypt,30 found patients with DM/
TB signiﬁcantly more likely to be male. While the bulk of studies
found no difference in the clinical presentation of DM/TB compared to
non-diabetic TB,29,42,48–51,54,60 two isolated reports found that
diabetics were more likely to present with hemoptysis.16,30
Regarding the duration of DM prior to patient presentation with
TB infection, a cross-sectional study from Iraq,29 which included
50 DM/TB patients, and another case–control study from Turkey
speciﬁcally aimed at evaluating features of DM/TB,42 respectively
reported that 56% and 40% of the DM/TB patients had had DM for at
least 10 years. Similarly, studies outside of the Middle East have
supported the theory of worse glycemic control as a marker of
disease severity predisposing to an increased rate of active TB
disease among diabetics.73–75 The aforementioned study from Iraq
found glycated hemoglobin (HgbA1c) to be poorly controlled
(>8%) in 48% of DM/TB patients.29 No prospective studies were
found that addressed how HgbA1c or another marker of DM
disease control changed with successful TB treatment.
Pulmonary TB is the most common anatomical presentation in
DM/TB infection, but it is unclear if patients with DM are more
likely to present with an extrapulmonary focus compared to
patients without DM.3 A few studies were found that addressed
this comparatively, but a study from Saudi Arabia suggested that
bone disease was more frequent in DM/TB compared to non-
diabetic TB.61 Furthermore, two related cases reported from
Turkey highlighted the presentation of spondylitis and bone
disease in DM/TB patients.50
There are conﬂicting data regarding the effect of DM on the
sputum smear results at the time of diagnosis of active pulmonary
TB infection.70,72,76 Studies from the Middle East offer no further
clarity. A case–control study from Turkey of patients with sputum
culture proven TB, found that those with DM/TB were signiﬁcantly
more likely to present with a negative AFB sputum smear upon
presentation compared to non-diabetic TB patients.51 In contrast,
the two other case–control studies from Saudi Arabia52 and
Egypt30 that had similarly found DM/TB patients more likely to be
male, concluded that DM/TB patients were more likely to have
positive AFB sputum smears upon presentation.
3.5. Radiological presentation
Similar to the conﬂicting data regarding clinical presentation in
DM/TB and non-diabetic TB, radiological appearances have often
been thought to be more atypical in DM/TB, but some reports have
demonstrated no appreciable between-group differences.3,70,71,77
The same conﬂict was observed in the Middle East studies, where
several showed clinical signiﬁcance in atypical imaging ﬁndings
(lower lobe/multiple lobe presentation and diffuse involve-
ment),51,54 other studies showed an increase in more typical
ﬁndings such as cavitary lesions in DM/TB-infected patients as
compared to non-diabetic TB patients,29,30,42,52 and yet another
ﬁve studies showed no difference.16,26,44,53,65
3.6. Drug-resistant TB
In certain settings, drug-resistant TB is associated with prior
anti-TB drug treatment or nosocomial exposure, which may be
more common in some subgroups like HIV-infected patients.78
Multidrug-resistant (MDR)-TB is deﬁned in the presence of
resistance to isoniazid and rifampicin, the two most important
ﬁrst-line anti-TB drugs. This predisposes the patient to a signiﬁcant
increase in morbidity and mortality when compared to drug-
susceptible TB.6 Whether DM presents any additional risk for thedevelopment or acquisition of MDR-TB remains controversial.79–81
Three case–control studies comparing DM/TB and non-diabetic TB
patients from Iran, Saudi Arabia, and Turkey showed no signiﬁcant
association between DM and the risk of MDR-TB.16,42,55 Addition-
ally, three studies assessed general risk factors for MDR-TB
infection among cohorts with TB. A retrospective study from
Israel covering the period from 2000 to 2005, described 132 MDR-
TB patients, of whom 17 (12.9%) had DM.67 In a national TB referral
hospital in Iran, 234 non-MDR pulmonary TB patients were
compared to 48 MDR pulmonary TB patients and DM was found in
6.4% in the MDR-TB group versus 9% in the non-MDR-TB group, a
non-signiﬁcant difference.27 This was also shown in another cross-
sectional study in Turkey (with a total of 116 sputum culture-
positive TB patients), where univariate analysis showed no
association between DM and MDR-TB.52
3.7. Pharmacokinetics
Several studies outside the region have suggested that patients
with DM/TB may be prone to suboptimal circulating anti-TB drug
concentrations, particularly rifampicin.82,83 A decrease in overall
peak or total exposure to a particular drug is dependent on
numerous factors, including host genetics related to xenobiotic
transport and metabolism, but may also be secondary to a decrease
in gastric hydrochloric acid secretion,83 gut transit time,84 and
weight or volume of distribution, which may all be more
problematic in the DM/TB patient.85,86
A single case–control study from Turkey addressed this topic.
Fourteen DM/TB patients and 56 non-diabetic pulmonary TB
patients were studied. The estimated peak plasma concentrations
of isoniazid and rifampicin were approximately 50% lower in the
DM/TB patients. All DM/TB patients had isoniazid and rifampicin
concentrations that were below the expected range. Pyrazina-
mide and ethambutol concentrations were similar in both
groups.47
3.8. Sputum conversion
Sputum conversion not only guides the duration of TB
treatment and infectivity of the patient, but delayed conversion
is also associated with an increased risk of relapse. While most
studies outside of the Middle East have shown no relationship
between DM and conversion at the end of 2 months,74,79 other
studies have shown an overall increased time to sputum
conversion,80,82 and in addition, DM/TB patients with HbA1c
values 7 have been observed to have a greater risk of a
persistently positive sputum culture at the end of 2 months.81 A
relatively large retrospective review at a TB referral hospital in
Turkey did not ﬁnd a statistically signiﬁcant difference in sputum
culture conversion at the end of 2 months of treatment, but the
duration of therapy was signiﬁcantly longer in DM/TB patients.42
Furthermore, another study from a referral hospital in Turkey
speciﬁcally addressed risk factors for delayed sputum conversion.
Among 306 patients, of whom 14% had DM, DM/TB was
signiﬁcantly associated with a delay in the time to both smear
and culture conversion.43 Another case–control study from Turkey
supported these ﬁndings.44 Additionally, in a study from Saudi
Arabia, DM was signiﬁcantly associated with persistent sputum
positivity after 2 months of treatment, but regression analysis
found age and disease burden (number of bacilli in pretreatment
sputum and cavitary lung disease) were the dominant predictors
overall.57 Lastly, one study from Oman in which 112 pulmonary TB
patients were treated for 2 months in the hospital before sputum
for AFB smear was repeated (repeat TB culture was not performed),
rates of smear conversion were similar for DM/TB and non-DM/TB
patients.66
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In the aforementioned study from Turkey,42 DM/TB patients
were more likely to require more than 6 months to achieve cure for
pulmonary TB compared to non-diabetic TB patients. In a study
from Egypt speciﬁcally carried out to study the risk factors for TB
treatment failure,34 119 patients with treatment failure were
matched to an equal number who had been successfully cured and
the presence of DM increased the risk of failure by more than 9-
fold, including among those with reported adherence under a
directly observed TB treatment schedule. Another retrospective
study done in a TB referral center in Iran included the medical
records of 715 pulmonary TB patients seen over a 15-year span, of
whom 75 had died during therapy.15 On multivariate analysis, DM
was independently associated with mortality (adjusted odds ratio
9.6, 95% conﬁdence interval 5.7–16.1, p < 0.001).23 Moreover, a
study from Kuwait assessed the prevalence and risk factors for
default from pulmonary TB treatment and found that DM/TB
patients were at increased risk of default in the adjusted analysis
compared to non-diabetic TB patients.39 Comparatively, four other
less rigorous studies showed no association of DM and poor
treatment outcome.55,61,67,68
4. Discussion
DM prevalence among patients with TB will continue to
increase given the projected global expansion of DM,72 and many
countries of the Middle East region appear particularly vulnerable.
The studies summarized from the Middle East demonstrated high
co-prevalence rates, with a prevalence of DM among TB patients
ranging from approximately 5% to more than 40%. The vast
majority of studies were retrospective analyses without a speciﬁc
design to compare DM/TB and non-DM/TB patients, and while
certain countries had numerous studies (Turkey, Iran, and Saudi
Arabia), there were six countries for which studies of DM/TB were
not found (Bahrain, Cyprus, Jordan, Lebanon, Syria, and UAE).
Despite the recommendation to screen for DM in patients with
active TB,4 there were no studies that examined the best method or
could comment on the diagnostic yield, even though in many
referral hospitals in Middle Eastern countries such screening is
practiced routinely. Furthermore, only one study examined the
role of screening patients with DM for active TB and suggested this
may be of clinical beneﬁt. Yet the widespread adoption of such
screening would certainly depend upon cost-effectiveness anal-
yses, including the method of screening (symptoms, sputum
diagnostics, and/or imaging) and local TB prevalence. Similarly,
studies of screening and treatment for latent TB infection in
patients with DM were not found. Hence, more comprehensive
local studies of bidirectional screening appear urgently needed
given the relative public health urgency of the DM/TB problem in
the region.
The bulk of studies examined hospitalized patients with TB and
either directly compared DM/TB patients and non-diabetic TB
patients,16,19,25,28,30,36,37,42,44,47–51,54,55,65 or reported DM among
numerous other clinical and demographic factors. Either very little
difference or conﬂicting reports were noted with regard to the
clinical presentation16,28,30,42,48,49,51,52,55,61 and radiographic ﬁnd-
ings16,26,29,30,42,44,51,53,54,65 in DM/TB compared to non-DM/TB. Yet
these investigations appear of less research importance compared
to the ﬁndings that patients with DM/TB may have a delay in
microbiological response to treatment43,44,57 and an increased risk
of death,15,23 which could be related to their disease burden at
presentation, underlying immune dysregulation,19,28,36,37 im-
paired pharmacological exposure,47 or simply that DM may
associate with other morbidities (e.g., renal dysfunction) that
may not have been reported or adequately adjusted for in analyses.It was not possible to examine other potential confounders in the
studies that reported on treatment outcome. For example, the
common anti-diabetic drug, metformin, has recently been
suggested to have direct anti-TB activity.93
With the knowledge gaps identiﬁed in this review, there exists
considerable potential for meaningful study of DM/TB in the
region. In many TB-endemic countries, DM care is unavailable,
poorly accessed, or restricted due to the poor supply and high costs
of drugs or lack of specialists.89–91 In contrast, a comparatively high
availability of DM care is present in many countries of the Middle
East. Saudi Arabia, Bahrain, Oman, and Qatar were among the top
10 countries with the highest health expenditure for DM as
measured by percentage of the national health expenditure in
2010.92 Therefore the integration of DM and TB services in these
countries may be more feasible and cost-effective.6,71,72,92 Other
target areas for research should focus on understanding and
optimizing DM/TB treatment outcomes87, which may include
study of intensiﬁed TB treatment regimens, therapeutic drug
monitoring,88 optimal duration of TB therapy, or the use of
adjunctive or immunomodulating agents.
In conclusion, a review of studies published from the Middle
East found a relative lack of investigation speciﬁcally designed to
assess differences in DM/TB compared to non-DM/TB. Future
studies should account for DM disease severity and anti-diabetic
treatment, as well as assure laboratory conﬁrmed absence of
hyperglycemia in subjects categorized as non-diabetic. Opportu-
nity exists for the study of bidirectional screening, management
strategies for both DM and TB diseases, and whether such efforts
could take place through the integration of services.
Conﬂict of interest: No conﬂict of interest to declare.
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